Dr. Leath on Ongoing Trials for Endometrial Cancer

Charles A. (Trey) Leath, III, MD
Published: Friday, Jun 09, 2017



Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Endometrial cancer is the most common gynecologic cancer, explains Leath. However, there is a lot that is unknown regarding the ideal treatment for endometrial cancer.

The PORTEC-3 and GOG 258 compared chemotherapy with various approaches of chemoradiation therapy. Standard chemotherapy has been beneficial; however, the role of radiation needs to be investigated further, states Leath.
 
SELECTED
LANGUAGE


Charles A. (Trey) Leath, III, MD, associate professor, UAB School of Medicine, UAB Comprehensive Cancer Center, discusses ongoing trials for patients with endometrial cancer.

Endometrial cancer is the most common gynecologic cancer, explains Leath. However, there is a lot that is unknown regarding the ideal treatment for endometrial cancer.

The PORTEC-3 and GOG 258 compared chemotherapy with various approaches of chemoradiation therapy. Standard chemotherapy has been beneficial; however, the role of radiation needs to be investigated further, states Leath.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x